MiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion
By Katherine Hamilton
MiniMed shares rose after the company posted higher-than-expected revenue and expanded its partnership with Abbott Laboratories.
The stock advanced 7% to $13.14 in pre-market trading Wednesday.
The provider of diabetes management technology posted $837 million in sales in the fiscal fourth quarter, ahead of the $827.9 million analysts polled by FactSet expected.
Revenue growth was driven by a 22% increase in international sales.
MiniMed also said it expanded its agreement with Abbott to commercialize glucose-ketone sensors designed to integrate exclusively with MiniMed's smart dosing systems.
The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott. It will bring expanded choice to MiniMed users across automated insulin delivery and Smart MDI systems.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
June 03, 2026 09:49 ET (13:49 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States